CD56 (NCAM) Monoclonal Antibody (CMSSB), APC, eBioscience™, Invitrogen™

Description

Description: This CMSSB monoclonal antibody reacts with human CD56, also known as Neural Cell Adhesion Molecule (NCAM). CD56 is a highly glycosylated transmembrane molecule expressed by neurons and plays a role in the homotypic adhesion of neural cells. In the hematopoietic system, CD56 is expressed on NK cells and a subset of T cells referred to as NKT cells. Staining with CMSSB does not block binding of MEM188 or CB56. Applications Reported: This CMSSB antibody has been reported for use in flow cytometric analysis. Applications Tested: This CMSSB antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 μL (0.125 μg) per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser. Filtration: 0.2 μm post-manufacturing filtered.

CD56 (NCAM, neural cell adhesion molecule) is a transmembrane glycoprotein of the immunoglobulin family that serves as an adhesive molecule and is ubiquitously expressed in the nervous system in isoforms ranging from 120-180 kDa. CD56 is found on T cells and NK cells, and is involved in cell migration, axonal growth, pathfinding and synaptic plasticity. Polysialic modification results in reduction of CD56-mediated cell adhesion. Through its extracellular region, CD56 mediates homophilic and heterophilic interactions by binding extracellular matrix components such as laminin and integrins. CD56 is expressed on most neuroectodermal derived cell lines, tissues and neoplasms such as retinoblastoma, medulloblastoma, astrocytomas and neuroblastoma. Further, CD56 is a widely used neuroendocrine marker with a high sensitivity for neuroendocrine tumors and ovarian granulosa cell tumors. Diseases associated with CD56 dysfunction include rabies and blastic plasmacytoid dendritic cell neoplasms.